Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by C10H12N2on Dec 28, 2021 7:02pm
78 Views
Post# 34266267

RE:RE:RE:RE:RE:Question for Whalewatcher

RE:RE:RE:RE:RE:Question for WhalewatcherROTFLMAO. You don’t believe they have an understanding of the uplist. Meanwhile, you need to be pointed to the correct page of the Nasdaq Guidelines. Now you're an expert based on Andre Uddin (yeah, you talked to him today) and your pick of stocks out in the world as a supposed quantifier of facts. Around in circles you go. Where you stop nobody knows. Nodayrader gave you a clear understanding of your misunderstandings. Yet, here you are again wanting to pick the same bone with me. Go answer Nodaytraders post. You're off on a tangent about what some other stocks do on Nasdaq beyond their prior exchanges. What you fail to hash out is what were each of their circumstances pre and post uplist. Did they do an IPO or was it a Direct Listing? Meanwhile, you don't know and you don't know the difference between the two without going back and reading my post about it. You just keep throwing sh!!!! at the wall hoping someone else believes you know what you’re talking about. You don't and to keep stating the same thing over and over again does border on going crazy over it. Screw what other companies have done. I care less. What I care about is what's right in front of me. Go talk to Algernon management and provide them with your Capital Markets wisdom and understanding. You're right. I'm wrong. Let's move on here >>>
<< Previous
Bullboard Posts
Next >>